Edoxaban is an anticoagulant (“blood thinner”) used in adults with non-valvular atrial fibrillation to help prevent stroke and systemic embolism. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrence. 💡
These conditions can have a significant impact on patients’ lives and require effective and reliable treatment to help reduce the risk of serious complications. By expanding the availability of Edoxaban across major European markets, including further launches planned in 2027, we are advancing broader access to essential therapies. 🌍
The 30 mg and 60 mg tablets have been developed and manufactured in-house by Tiefenbacher Laboratories and are marketed by one of our partners. This milestone reflects our continued commitment to improving patients’ lives through better affordability, better access, and better therapies. 💙
